An FDA advisory panel is meeting to determine whether to allow seven types of peptides to be sold as compounded medications, despite ongoing concerns from medical experts regarding safety data.
Key facts
- •The FDA advisory panel meeting is scheduled for July 23–24.
- •The Biden administration restricted 19 peptides in 2023, including the seven currently under review.
- •Proponents claim the peptides can aid in injury recovery and wellness, while critics cite a lack of human clinical evidence.
- •FDA scientists have posted documents expressing concerns regarding the safety and scientific review of the substances.
- •Compounded medications require a prescription and are intended for patients whose medical needs cannot be met by FDA-approved drugs.
An FDA advisory panel is scheduled to meet July 23–24 to vote on whether to loosen restrictions on seven specific peptides. If approved, these substances could be prepared and sold as compounded medications by pharmacies in the United States. The Biden administration previously restricted these 19 peptides in 2023, effectively prohibiting compounding pharmacies from producing them.
Debate Over Safety and Efficacy
Proponents, including Health and Human Services Secretary Robert F. Kennedy Jr., have touted these peptides as potential treatments for conditions such as obesity, migraines, wound healing, and ulcerative colitis. Some advocates describe them as a "fountain of youth" that can improve muscle mass and longevity. Conversely, several medical professionals have raised significant concerns, noting that many of these peptides lack sufficient human clinical trials, pharmacology, and toxicology data. Dr. Katrin Svensson of Stanford University and Dr. David Cutler of Providence Saint John’s Health Center emphasized that the lack of systematic study makes it difficult to determine the risks of chronic administration. Dr. Bert Mandelbaum, an orthopedic surgeon, characterized the trend as an "uninformed fad" and warned against using substances that have not been adequately vetted for safety.
Regulatory Context and Potential Outcomes
While some peptides like insulin and GLP-1 medications are FDA-approved for specific conditions, the agency has previously issued warnings regarding the safety of compounded versions of GLP-1 drugs. Dr. Mir Ali, a bariatric surgeon, suggested that broadening the application of these medications might allow the medical community to gather more data, though he acknowledged that the full extent of their risks and benefits remains unknown. Any recommendation made by the advisory panel during the upcoming meeting will still require final approval from FDA administrators.
Timeline
- 2023The Biden administration placed restrictions on 19 peptides, effectively banning their production by compounding pharmacies.
- JuneFDA officials issued a warning regarding the safety of compounded GLP-1 medications.
- July 23–24An FDA advisory panel is scheduled to vote on whether to ease restrictions on seven specific peptides.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Healthline.
